Revision of Helsinki Declaration

Similar documents
WMA Declaration of Helsinki - Ethical

WMA Declaration of Helsinki Ethical Principles f or Medical Research Involving Human Subjects

World Medical Association Declaration of Helsinki

Strengthening ethics review systems

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience

An ethical dilemma: Moving medical research to the developing countries. By: Qianyao Qiu

European Medicines Agency Perspective

June 14, To the World Medical Association Secretariat:

MRCT Center Post-Trial Responsibilities Framework. Continued Access to Investigational Medicines

Ethical Issues, Community Perspective and Standards of Care for Clinical Research on Women & Children in Africa

INSTITUTIONAL ETHICS REVIEW COMMITTEE GLOSSARY

3. Human Biomedical Research. Defining Human Biomedical Research

MRCT Center Post-Trial Responsibilities Framework. Continued Access to Investigational Medicines

Hospital Authority (HA) Guide on Research Ethics (for Study Site & Research Ethics Committee)

ISPE Comments on the CIOMS 2006 draft Special Ethical Considerations for Epidemiologic Research 1

Discussions of the ethics of research involving human

Post-Trial Responsibilities

Ethical Principles in Clinical Research. Disclaimer. Christine Grady Department of Bioethics NIH Clinical Center

Ethical, Legal and Social Issues arising out of Advancements in New Biology. Seyed E. Hasnain

CIOMS International Ethical Guidelines for Biomedical Research Involving Human Subjects Revised draft, January 2002

Ethical Principles in Clinical Research

Outline 18/11/14. Implementation of the DoH in the Americas: Challenges and successes. ! Background and context. ! United States. !

JOB DESCRIPTION. 35 hours per week (unsocial hours will be required at times) This post is funded by ESF effective from 1 April 2018 to 31 March 2022

Streamlining IRB Procedures for Expanded Access

Ethics and Clinical trials EU approach

Human Genome Editing: Science, Ethics, and Governance Highlights for Industry Stakeholders

Guiding Principles on the Sharing of Clinical Trial Data. DNDi POLICIES

CODE OF PRACTICE FOR RESEARCH

International Ethical Guidelines for Biomedical Research Involving Human Subjects

MEDICAL ETHICS: INTRODUCTION AND HISTORY OF BIOETHICS

SAE Reporting Timelines, Causality Assessment And Compensation. Pawandeep Kaur Associate Medical Director CDSA

Application form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE

Brain Tumour Australia Information FACT SHEET 22 Clinical Trials: Questions and Answers

Long-Term Follow-Up in Gene Transfer Clinical Research

Expert Conference on Revision of Declara?on of Helsinki Tokyo, Japan. On March 1, 2013 Professor Somkiat Wa/anasirichaigoon, MD, FRCST

CAN GDPR WORK FOR HEALTH SCIENTIFIC RESEARCH? BRUSSELS OCTOBER 22 ND CIPL EFPIA FPF EXECUTIVE SUMMARY

HOSPITAL AUTHORITY (HA) GUIDE

FACTS YOU NEED TO KNOW UNITED STATES OF AMERICA

Functional Classification of Medicine

POSITION DESCRIPTION

Data & Materials Sharing Agreement. Collaboration for AIDS Vaccine Discovery. Clinical Trials Data Sharing Addendum & Related Information

Reconsidering the Ethical Permissibility of the use of Unregistered Interventions against Ebola Virus Disease

Joint statement on public disclosure of results from clinical trials

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949

OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE

Research, Human Subject Protection & Institutional Review Board (IRB) Jed Delmore, MD

DEVELOPING CLINICAL TRIALS INFRASTRUCTURE

PERFORMANCE IN INITIATING AND DELIVERING CLINICAL RESEARCH INFORMATION SUBMISSION GUIDELINES

ClinicalTrials.gov REGISTRATION REQUIREMENTS

Classroom Discussion Guide on Ethics and Public Health Emergencies

Regulatory and ethics bodies involved in approval process. CA - Registration requirements for clinical trials

GUIDELINES FOR CONDUCTING CLINICAL TRIALS.

Structure and Mandate of FDA

ClinicalTrials.gov Registration and Results Reporting: Updates and Recent Activity

The Schar School of Policy and Government George Mason University (GMU) December 11 th, 2017

TOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH

HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP)

While individually rare, orphan diseases are actually collectively common, with an OF ORPHAN DRUG DEVELOPMENT MEETING THE UNIQUE CHALLENGES

Memorandum to the Code of Conduct

1. Practice experience reports versus research projects subject to EC approval (Appendix 1)

The World Medical Association s Declaration of Taipei

Clinical Research: A Multifaceted Discipline

Compliance mechanisms available in Russia to ensure adherence to ethical guidelines

GCP Basics - refresher

Biomedical Research on Human Participants

Good Clinical Practice

BO STO N MEDTECH. More Experience Better Results. Ethics in Clinical Research. Zvi Ladin, Ph.D.

USE OF INVESTIGATIONAL DRUGS OR BIOLOGICS IN HUMAN SUBJECTS RESEARCH

Florida State University Policy 7-IRB-

Journal. of Health Law. Ethical Issues in International Biomedical Research: An Overview. Alice K. Page. Fall 2004 Volume 37, No.

MRC. Clinical Trials. Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS. Medical Research Council

Agenzia Italiana del Farmaco

Clinical trials from CRA s point of view

Current Issues Regarding Data and Safety Monitoring Committees in Clinical Trials

Virtual Mentor American Medical Association Journal of Ethics February 2007, Volume 9, Number 2:

A notice on the issuance of drug clinical trials, ethical review of the guiding principles

S A I N T M A RY S E M I N A RY O C T O B E R 1 9,

Effective Date: April 2014 Revision: September 29, 2017

Annual Research Administrators Symposium IRB Compliance. Thursday, July 31, 2014

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

Office for Human Subject Protection. University of Rochester

Exploring Good Clinical Practice guidance in clinical trials meeting summary

Research: Ethics, Informed Consent, FDA, Off Label Use

Digging Deeper: Focus on Best Practices Medical Affairs Compliance

Volunteering for Clinical Trials

National Health Research Systems and Regulations for Ethical Research in Indonesia

Competent federal higher authority ("Bundesoberbehörde- BOB")

Version Number: 004. On: June 2018 Review Date: June 2021 Distribution: Essential Reading for: Information for: Page 1 of 10

Amanda A. Hastings, MSHL Education Specialist USF Division of Research Integrity & Compliance

Sponsorship of Clinical Research Studies

Clinical trial regulation and ethical committees EAHP statements

EU Clinical Trials Regulation 536/2014

R&D for potential vaccines for the Ebola virus

UNIVERSITY RESEARCH ETHICS COMMITTEE RESEARCH ETHICS POLICY AND PROCEDURES. 8th Edition (2017)

Standards of proficiency. Biomedical scientists

Re: Docket No. FDA-2015-D-4562: Draft Guidance Safety Assessment for IND Safety Reporting

PART 1. DRAFT GUIDING PRINCIPLES ON HUMAN ORGAN TRANSPLANTATION

International Transfers of Personal Data at sanofi-aventis R & D

WMA Satellite Meeting The future of the Declaration of Helsinki

International Ethical Guidelines for Epidemiological Studies

Transcription:

World Medical Association Revision of Helsinki Declaration Post Study Access or What Happens once Research is Over? Dr Fazel Randera Cape Town December 2012

Context In 2000 the WMA added a new provision to the Declaration of Helsinki stating that at the end of the study, patients entered into the study are entitled to be informed about the outcome of the study and to share any benefits that result from it, for example access to interventions identified as beneficial in the study or to other appropriate care or benefits. International controversy ensued over the implications of this new provision and the WMA issued a clarification note in 2004. The most recent version (2008) amended the paragraphs relating to post-trial access: the protocol should describe arrangements for post-study access by study subjects to interventions identified as beneficial in the study or access to other appropriate care or benefits.

Relevant Paragraphs The Declaration emphasizes that it should be read as a whole and each of its constituent paragraphs should not be applied without consideration of all relevant Paragraphs 1. The Declaration of Geneva of the WMA binds the physician with the words, the health of my patient will be my first consideration, and the International Code of Medical Ethics declares that, A physician shall act in the patient s best interest when providing medical care 2. In medical research involving human subjects, the well being of the individual research subject must take precedence over all other interests 3. It is the duty of physicians who participate in medical research to protect the life, health, dignity, integrity,, right to self determination, privacy and confidentiality of personal information of research subjects 4. The protocol should describe arrangements for post-study access by study subjects to interventions identified as beneficial in the study or access to other appropriate care or benefits 5. Medical research involving a disadvantaged or vulnerable population or community is only justified if the research is responsive to the health needs and priorities of this population or community and if there is a reasonable likelihood that this population or community stands to benefit from the results of the research 6. The primary purpose of medical research involving human subjects is to understand the causes, development and effects of diseases and improve preventive, diagnostic and therapeutic interventions. Even the best current interventions must be evaluated continually through research for their safety, effectiveness, efficiency, accessibility and equality

Context (1) Council for International Organizations of Medical Sciences (CIOMS) In collaboration with WHO in 2002- For research conducted in communities with limited resources- the sponsor and the investigator must make every effort to ensure that any intervention or product developed, or knowledge generated, will be made reasonably available for the benefits of that community or population and if an investigational drug has been shown to be beneficial, the sponsor should continue to provide it to the subject after the conclusion of the study and pending its approval by the drug regulatory authority

(2) CIOMS International Guidelines for Ethical Review of Epidemiological Studies Where findings could be applied in public health measures to improve community health, they should be communicated to the health authorities...research protocols should include provision for communicating such information to communities and individuals Principle 13 While studies are in progress, particularly in developing countries, the opportunity should be taken to train local health workers in skills and techniques that can be used to improve health services. For instance, by training them in the operation of measuring devices and calculating machines, when a study team departs it leaves something of value, such as the ability to monitor disease or mortality rates. Principle 17

(3) CIOMS International Guidelines for Ethical Review of Epidemiological Studies As a general rule, the sponsoring agency should ensure that, at the completion of successful testing, any product developed will be made reasonably available to inhabitants of the undeveloped community in which the research was carried out; exceptions to this general requirement should be justified. Commentary on guideline 8 Consideration should be given to whether the sponsoring agency should agree to maintain the host country, after the research has been completed, health services and facilities established for purposes of this study. Commentary on guideline 15 The research protocol should specify what, if any resources, facilities and other goods or services will be made available. After the research to the community from which the subjects are drawn and to the host country. Commentary on guideline 15

(4) UNAIDS Ethical considerations in HIV Preventive Vaccine Research (2000) Any HIV preventive vaccine demonstrated to be safe and effective, as well as other knowledge and benefits resulting from HIV vaccine research, should be made available as soon as possible to all participants in the trials which it was tested, as well as other populations at high risk of HIV infection. Plans should be developed at the initial stages of HIV vaccine development to ensure such availability. Guidance point 2 Strategies should be implemented to build capacity in host countries so that they can practice meaningful self determination in vaccine development, can ensure the scientific and ethical conduct of vaccine development, and can function as equal partners with sponsors and others in a collaborative process. Guidance point 3

(5) USA and some major Sponsors The US Code of Federal Regulations does not mention post trial access. Some major sponsors of research are prohibited from funding post trial access (NIH) or state that their remit excludes this (Wellcome Trust, 2004)

(6) MRC Guidelines on Ethics for Medical Research There should be benefit to a host country community in which research is undertaken, such as access to the best proven prophylactic, diagnostic and therapeutic methods identified in the study

Thank You